CG Invites Co

CG Invites Co Gross Margin

The Gross Margin of CG Invites Co (083790.KQ) as of Oct 28, 2026 is -7.09 %. In the previous year, Gross Margin was -7.16 % — a change of -0.96% (higher).

Gross Margin

-7.09 %

YoY

-0.96%

Last updated:

Gross Margin of CG Invites Co is 2025 -7.09 % . Gross Margin of CG Invites Co was 2024 -7.16 % . It decreases by -0.96% higher compared to the previous year.

For CG Invites Co, the gross margin of -7.1% is down versus 51.2% a few years ago.

The CG Invites Co Gross Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Gross Margin
Date
Gross Margin
Jan 1, 2018
79.10 KRW
Jan 1, 2019
34.31 KRW
Jan 1, 2020
42.72 KRW
Jan 1, 2021
51.23 KRW
Jan 1, 2022
98.77 KRW
Jan 1, 2023
29.86 KRW
Jan 1, 2024
-7.16 KRW
Jan 1, 2025
-7.09 KRW
The CG Invites Co Gross Margin history
YEARGross MarginYoY
-7.09 %-0.96%
-7.16 %-123.96%
29.86 %-69.76%
98.77 %+92.83%
51.23 %+19.91%
42.72 %+24.50%
34.31 %-56.62%
79.10 %+8.93%
72.62 %+9.10%
66.56 %-29.82%
94.84 %+33.57%
71.01 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

CG Invites Co Stock analysis

What does CG Invites Co do? CrystalGenomics, Inc. generates revenue through its Finished Pharmaceuticals Manufacturing segment, which produces and sells finished pharmaceuticals. The Pharmaceutical R&D Division provides clinical trial analysis and technical services while also selling new drugs. The company also operates in the real estate leasing business under the segment structure. The Others segment manufactures and sells hot fats and other household items. Revenue streams are derived from pharmaceutical manufacturing, R&D services, real estate leasing, and household product sales. The primary buyers for finished pharmaceuticals include healthcare providers and distributors. Clinical trial analysis and new drug sales target pharmaceutical companies and research institutions. Real estate leasing serves commercial tenants, while hot fats and household items are sold to retail consumers. The company's segments collectively serve diverse markets across healthcare, real estate, and consumer goods. CrystalGenomics, Inc. focuses on therapeutic discovery and development, with its R&D Division driving innovation in new drug sales. The Finished Pharmaceuticals Manufacturing segment ensures steady supply of established products. Real estate leasing and household item sales provide additional revenue streams. The company's business model integrates pharmaceutical production, research, and non-pharmaceutical ventures. CG Invites Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about CG Invites Co stock

Gross Margin of CG Invites Co is -7.09 % in 2025.

Gross Margin of CG Invites Co changed from -7.16 % to -7.09 %, representing a -0.96% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Gross Margin CG Invites Co since 2006 – with annual values, charts, and detailed analysis.

Gross Margin measures the percentage of revenue remaining after COGS. Higher gross margins indicate more efficient production and stronger pricing power.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Gross Margin's CG Invites Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Gross Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Gross Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — CG Invites Co

All Key Metrics — CG Invites Co